Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Du bruger tilsyneladende en bredere skærm. Vil du gerne give denne side en bredere visningsoplevelse?

Zerion Pharma – Regulatory environment and strategic partnerships

Af HC Andersen Capital
Zerion Pharma

Meet Zerion Pharma’s management and regulatory team – CEO Ole Wiborg, CFO Jakob Dynnes Hansen, and Mónica González VP Regulatory Affairs. Management will briefly run through the investment proposal and business case. Then management will focus on the regulatory environment governing the Dispersome™ technology, formulation of new drugs, and reformulation of existing drugs. Last but not least CEO Ole Wiborg will give a little flavor on the company’s strategic partnerships.

Zerion Pharma is a non-listed Danish company seeking €2-3m in a private placement round.

The company aims to make a real difference in health care with its Dispersome™ technology in relation to the formulation of new and existing drugs. Poor drug solubility is one of the main reasons for drug development failure. ZERION has a solution - Dispersome® - a technology that increases the chance of success for new drug development, allows for improvement of existing drugs enabling more new drugs to reach the market and leads to improved treatment of patients as well as reduced toxic waste. The Dispersome® technology makes it possible to reduce the number of active drugs by up to 75%.

Disclaimer: HC Andersen Capital receives payment from Zerion Pharma for a Digital IR/Corporate Visibility agreement. Zerion Pharma is a private company (i.e. not listed on a regulated stock market). Investors should therefore be aware of the potential risks that can be associated with investing in a private company, including liquidity conditions, how shares are traded as well as the process of the specific capital raise. /Claus Thestrup 9.49 PM 09-02-2023.

A recording of the event will be available per request. Please contact mie@hcandersencapital.dk to know more.

Seneste videoer

HCA Morgenbørs 12/12 - Positive futures og fokus på FLSmidth og fedme aktier
12.12.2025, 09.27 Novo Nordisk
A sit-down with CEO Remco Westermann
12.12.2025, 09.09 Verve Group
Aiforia as an Investment | Life Science Night Dec 9, 2025
11.12.2025, 11.00 Aiforia Technologies
HCA Morgenbørs 11/12 - Flade europæiske futures, Oracle skaber usikkerhed om AI
11.12.2025, 09.45 GreenMobility
Endomines as an Investment | Investor Day Nov. 24, 2025
10.12.2025, 12.30 Endomines Finland
Vis alle videoer
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.